VNDRIQ — Vendor Comparison
Craniocatch vs CellmatiQ
Side-by-side comparison of BAA status, PHI exposure, AI training risk, HIPAA suitability, and VNDRIQ governance scores.
Craniocatch
Dental Imaging AI
Verification pending
CellmatiQ
Dental Imaging AI
Verification pending
VNDRIQ Scores
41
Overall
35
Overall
Approval Tier
BAA Status
PHI Exposure Risk
AI Training Risk
HIPAA Risk Level
Review Frequency
Quarterly
Quarterly
Recommended Use
Educational and research purposes; clinical use is currently restricted in the United States due to the absence of FDA marketing authorization.
Automated cephalometric landmark identification and diagnostic support for dental pathologies in clinical settings.
Restrictions
Lacks verified FDA 510(k) clearance for clinical deployment within the United States as of recent regulatory reviews.
Primarily certified for the EU market (CE mark); FDA clearance for the US market is not confirmed in available documentation.
Executive Summary
Craniocatch
Dental Imaging AI
Craniocatch is classified as Restricted / Review Required with a BAA status of No publicly available Business Associate Agreement (BAA) was identified; the company is headquartered in Turkey and lacks verified FDA clearance for US clinical use.. PHI exposure is rated High and AI training risk is Medium. Educational and research purposes; clinical use is currently restricted in the United States due to the absence of FDA marketing authorization.
36
Privacy
37
Governance
35
Healthcare
55
AI Risk
CellmatiQ
Dental Imaging AI
CellmatiQ is classified as Restricted / Review Required with a BAA status of No public Business Associate Agreement (BAA) was identified in the search results; the company primarily emphasizes EU CE certification and GDPR compliance.. PHI exposure is rated High and AI training risk is High. Automated cephalometric landmark identification and diagnostic support for dental pathologies in clinical settings.
36
Privacy
37
Governance
35
Healthcare
30
AI Risk
Recommended For
Craniocatch
Educational and research purposes; clinical use is currently restricted in the United States due to the absence of FDA marketing authorization.
Currently under review — not recommended for active PHI deployment
CellmatiQ
Automated cephalometric landmark identification and diagnostic support for dental pathologies in clinical settings.
Currently under review — not recommended for active PHI deployment
Governance Considerations
Craniocatch
PHI exposure is elevated. Review data flow documentation.
Quarterly reviews are required — establish internal review cadence.
Restrictions noted: Lacks verified FDA 510(k) clearance for clinical deployment within the United States as of recent regulatory reviews.
CellmatiQ
Verify model training opt-out clauses before deployment.
PHI exposure is elevated. Review data flow documentation.
Quarterly reviews are required — establish internal review cadence.
Restrictions noted: Primarily certified for the EU market (CE mark); FDA clearance for the US market is not confirmed in available documentation.
Questions to Ask Before Approval
Has the vendor executed a Business Associate Agreement (BAA) with your organization?
Does the vendor use customer data to train AI models? Can you opt out?
Where is PHI stored, processed, and transmitted?
What data retention and deletion policies apply to your PHI?
Has the vendor undergone a third-party HIPAA or SOC 2 audit?
What is the vendor's incident response and breach notification process?
Does the vendor offer audit logging for PHI access?
What subprocessors have access to PHI through this vendor?
Request Vendor Evaluation
Get a structured risk assessment for any vendor.
Request Benchmark Report
Compare vendors across your full stack.
Book Governance Assessment
Talk to a VNDRIQ governance specialist.